Biosyntech Inc

Healthcare US BSYI

0.0USD
-(-%)

Last update at 2025-05-21T20:00:00Z

52 Week Range

-0.003
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap0.23M
  • Volume642
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.32087M
  • Revenue TTM0.20M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 0.02M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2009-03-31 2008-03-31 2007-03-31 2006-03-31 2005-03-31
Type yearly yearly yearly yearly yearly
Date 2009-03-31 2008-03-31 2007-03-31 2006-03-31 2005-03-31
Income before tax -1.60493M -7.35075M -2.18719M -1.69052M 0.00000M
Minority interest 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Net income -1.60493M -7.35075M -2.18719M -1.69052M 0.00000M
Selling general administrative 0.37M 2.91M 1.03M 0.72M 0.00000M
Selling and marketing expenses - - - - -
Gross profit 0.00308M 0.14M 0.04M 0.00989M 0.00000M
Reconciled depreciation - - - - -
Ebit -7.94398M -9.15878M -8.29544M -6.17826M 0.00000M
Ebitda - - - - -
Depreciation and amortization - - - - -
Non operating income net other 0.00000M 0.00000M 0.00000M 0.00000M -
Operating income -0.98538M -7.26324M -2.23622M -1.52362M 0.00000M
Other operating expenses 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest expense 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Non recurring 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Other items 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Income tax expense 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total revenue 0.00506M 0.22M 0.07M 0.02M 0.15M
Total operating expenses 0.99M 7.48M 2.30M 1.54M 0.00000M
Cost of revenue 0.00198M 0.08M 0.02M 0.00528M 3.64M
Total other income expense net -0.61956M -0.08751M 0.05M -0.16690M 0.00000M
Discontinued operations 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Net income from continuing ops -1.60493M -7.35075M -2.18719M -1.69052M 0.00000M
Net income applicable to common shares -12.93877M -9.26913M -8.11355M -6.85505M 0.00000M
Preferred stock and other adjustments 0.00000M 0.00000M 0.00000M 0.00000M -
Breakdown 2009-03-31 2008-03-31 2007-03-31 2006-03-31 2005-03-31
Type yearly yearly yearly yearly yearly
Date 2009-03-31 2008-03-31 2007-03-31 2006-03-31 2005-03-31
Total assets 0.89M 4.85M 4.43M 3.63M 3.94M
Intangible assets 0.00000M 0.00080M 0.16M 0.13M 0.39M
Earning assets - - - - -
Other current assets 0.00000M 0.00022M 0.00000M 0.00000M 0.06M
Total liab 1.72M 3.54M 1.41M 1.51M 5.39M
Total stockholder equity -0.82592M 1.31M 3.02M 2.12M 0.00000M
Deferred long term liab 0.00000M 0.00000M 0.36M 0.18M 0.00000M
Other current liab 0.17M 0.03M 0.04M 0.04M 0.24M
Common stock 50.61M 49.88M 49.88M 39.90M 19.42M
Capital stock - - - - -
Retained earnings -66.80371M -53.86495M -43.96576M -35.85220M 0.00000M
Other liab 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Good will 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Other assets 0.00276M 0.00276M 0.36M 0.18M 0.29M
Cash 0.47M 2.25M 1.09M 1.14M 0.75M
Cash and equivalents - - - - -
Total current liabilities 11.91M 1.92M 1.94M 4.25M 3.36M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt 1.26M 0.42M 0.16M 0.12M 0.00000M
Short long term debt total 0.00000M 0.00000M 0.00000M 0.00000M -
Other stockholder equity 3.67M 0.00000M 0.00000M 0.00000M 0.00000M
Property plant equipment 1.84M 2.20M 2.46M 2.58M 2.25M
Total current assets 5.36M 3.92M 13.03M 11.42M 0.00000M
Long term investments 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Net tangible assets -6.65843M 1.66M 10.61M 8.04M 0.00000M
Short term investments 0.00000M 0.00000M 2.13M 1.54M 0.00000M
Net receivables 1.34M 0.89M 0.85M 0.30M 0.00000M
Long term debt 0.24M 2.02M 0.89M 0.46M 2.04M
Inventory 0.06M 0.02M 0.01M 0.00330M 0.01M
Accounts payable 0.50M 0.65M 0.58M 0.48M 0.32M
Total permanent equity 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Noncontrolling interest in consolidated entity 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Temporary equity redeemable noncontrolling interests 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Accumulated other comprehensive income 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Additional paid in capital 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Common stock total equity 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Preferred stock total equity 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings total equity 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Treasury stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Accumulated amortization 0.00000M 0.00000M 0.00000M 0.00000M -
Non currrent assets other 0.00000M 0.00000M 0.00000M 0.00000M -
Deferred long term asset charges 0.00000M 0.00000M 0.00000M 0.00000M -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00000M -
Capital lease obligations 0.00000M 0.00000M 0.00000M 0.00000M -
Long term debt total 0.00000M 0.00000M 0.00000M 0.00000M -
Breakdown 2009-03-31 2008-03-31 2007-03-31 2006-03-31 2005-03-31
Type yearly yearly yearly yearly yearly
Date 2009-03-31 2008-03-31 2007-03-31 2006-03-31 2005-03-31
Investments 0.00000M 7.89M -1.63585M -6.24990M 0.00000M
Change to liabilities -0.04519M 0.02M -0.24663M 0.32M 0.11M
Total cashflows from investing activities -0.23264M 7.77M -1.98494M -6.50842M 0.57M
Net borrowings 11.96M -0.56827M -1.01897M -0.20580M 0.00000M
Total cash from financing activities 10.76M -0.58478M 8.91M 16.42M 1.89M
Change to operating activities 0.02M 0.07M -0.02598M -1.22283M 0.00000M
Net income -12.93877M -9.26913M -8.11355M -6.85505M 0.00000M
Change in cash 0.97M -1.20442M -0.59883M 3.74M 0.00000M
Begin period cash flow - - - - -
End period cash flow - - - - -
Total cash from operating activities -9.57318M -8.38576M -7.52458M -6.17431M 0.00000M
Issuance of capital stock - - - - -
Depreciation 0.36M 0.38M 0.41M 0.37M 0.00000M
Other cashflows from investing activities 0.00000M 0.00000M -0.10385M -0.09190M 0.00000M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory -0.03622M -0.00626M -0.01111M 0.00949M 0.00165M
Change to account receivables -0.06389M -0.00765M -0.05659M 0.02M 0.00000M
Sale purchase of stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Other cashflows from financing activities -1.19685M -0.01651M -1.07057M -0.66224M 0.00000M
Change to netincome 3.08M 0.36M 0.48M 0.99M 0.00000M
Capital expenditures 0.23M 0.12M 0.25M 0.17M 0.04M
Change receivables 0.00000M 0.00000M 0.00000M 0.00000M -
Cash flows other operating 0.00000M 0.00000M 0.00000M 0.00000M -
Exchange rate changes 0.00000M 0.00000M 0.00000M 0.00000M -
Cash and cash equivalents changes 0.00000M 0.00000M 0.00000M 0.00000M -
Change in working capital - - - - -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow - - - - -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BSYI
Biosyntech Inc
- -% - - - 1.15 - 0.58 -0.0099
NVO
Novo Nordisk A/S
-0.155 0.23% 68.05 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
0.95 1.40% 68.95 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.41 1.01% 430.91 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
-10.3 1.70% 594.32 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. Its lead products in development include BST-CarGel, a biodegradable gel for cartilage repair; BST-InPod for heel pain relief; BST-DermOn for chronic wound healing; BST-Ossifil for bone filling; BST-Ossifix for bone structural support; and BST-Disc for intervertebral disc restoration. The company's products also comprise BST-Gel-based injectable products that deliver biotherapeutics to their targeted site of action; Arthro-BST, an arthroscopic device used for the non-destructive evaluation of cartilage degradation and/or repair; and Mach-1, a micromechanical testing system for evaluating the mechanical properties of tissues and materials. In addition, it manufactures ultra pure chitosans under the Ultrasan name; and offers manufacturing and analytical services. The company was incorporated in 1994 and is based in Laval, Canada. On May 12, 2010, Biosyntech Inc. filed for administration under the Bankruptcy and Insolvency Act. Biosyntech Inc. is in reorganization.

Biosyntech Inc

475 Armand-Frappier Boulevard, Laval, QC, Canada, H7V 4B3

Key Executives

Name Title Year Born
Dr. Amine Selmani Ph.D. Founder & Advisor 1957
Dr. Alberto Restrepo M.D. Director of Medical Affairs NA
Ms. Catherine Auld C.A. Chief Financial Officer NA
Ms. Lucie Duval Controller 1959
Ms. Lucie Duval B.A.A Controller 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.